



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/566317/2013

European Medicines Agency decision

P/0238/2013

of 24 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for insulin peglispro, (EMA-001097-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0238/2013

of 24 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for insulin peglispro, (EMA-001097-PIP01-10-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0101/2012 issued on 30 May 2012,

Having regard to the application submitted by Eli Lilly and Company on 20 May 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 August 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for insulin peglispro, solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eli Lilly and Company, Research Centre, Erl Wood Manor, Sunninghill Road, GU20 6PH – Windlesham, United Kingdom.

Done at London, 24 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/329748/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001097-PIP01-10-M01

Scope of the application

Active substance(s):

Insulin peglispro

Condition(s):

Treatment of type 1 diabetes mellitus

Treatment of type 2 diabetes mellitus

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

Eli Lilly and Company

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company submitted to the European Medicines Agency on 20 May 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0101/2012 issued on 30 May 2012.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 12 June 2013.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified. A deferral for initiation of study 3 has been agreed.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 9 August 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of Type 1 Diabetes Mellitus

The waiver applies to:

- Children from birth to less than 6 years of age,
- for solution for injection, subcutaneous use,
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfill a therapeutic need in the paediatric population.

1.2. Condition: Treatment of Type 2 Diabetes Mellitus

The waiver applies to:

- Children from birth to less than 10 years of age,
- for solution for injection, subcutaneous use,
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

and to:

- Children from 10 to less than 18 years of age,
- for solution for injection, subcutaneous use,
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfill a therapeutic need in the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of Type 1 Diabetes Mellitus

2.1.1. Indication(s) targeted by the PIP

Treatment of Type 1 Diabetes Mellitus.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection.

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable.
Non-clinical	1	Study 1: 10-week juvenile repeat dose toxicity study in rats to investigate potential effects on the developing nervous system.
Clinical	2	Study 2: Randomised, active-controlled (insulin glargine), open-label, multicentre, 28-day, parallel-arm, PK/PD, safety and tolerability study in patients with type 1 diabetes mellitus (T1DM) using basal insulin (insulin peglispro) in combination with bolus insulin (insulin lispro). Study 3: Randomised, active-controlled (insulin glargine), open-label, multicentre, 52-week parallel-arm, safety and efficacy study in patients with T1DM using basal insulin (insulin peglispro) in combination with bolus insulin (insulin lispro).

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more measures contained in the paediatric investigation plan:	Yes